Massive taiwan study reveals COVID-19 treatment patterns
NCT ID NCT06085924
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study used health records from over 8 million people in Taiwan to understand the effects of COVID-19 and how well the oral treatment nirmatrelvir/ritonavir works. Researchers looked at who got severely ill, needed hospital care, or died, and compared those who took the treatment with those who did not. The goal was to learn more about the disease and the real-world use of this medication.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer Taiwan
Taipei, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?